-
Key Brands
-
Revenue
-
Performance
| Eltroxin | Imuran | Lipitor | Lyrica | Meticorten | Purinethol |
|---|---|---|---|---|---|
|
Thyroid hormone |
Immunosuppressant |
Cardiovascular |
Anticonvulsant |
Corticosteroid |
Oncology |
Revenue by segment (%)
25%
of Group revenue
36%
of Group gross profit
- Africa Middle East 45
- Australasia 39
- Americas25
- Asia6
- Europe CIS6
Revenue
| Revenue |
2024 R’million |
2023 R’million |
%Change Reported |
CER |
|---|---|---|---|---|
|
Africa Middle East |
4 242 |
3 876 |
9 |
9 |
|
Americas |
2 832 |
1 801 |
57 |
42 |
|
Australasia |
2 618 |
2 713 |
(4) |
(6) |
|
Europe CIS |
991 |
989 |
- |
(7) |
|
Asia |
697 |
542 |
29 |
24 |
|
Total |
11 380 |
9 921 |
15 |
11 |
|
Gross profit (%) |
60,9 |
60,7 |
|
|
Prescription brands achieved robust growth of 15%, with revenue reaching R11 380 million. This was
primarily driven by the Americas, which posted a 57% increase supported by both organic and
acquisition-led growth. Asia grew by 29%, benefiting from a 7% increase in organic growth alongside
acquisitive gains. Africa Middle East, the largest region in this segment, reported strong organic growth
of 9%. Europe CIS remained flat while Australasia experienced a 4% decline due to regulated price
reductions in Australia.
The gross profit margin rose to 60,9% (FY2023: 60,7%), with the positive impact of the favourable sales mix more than offsetting the effects of regulated price cuts in Australia.
The gross profit margin rose to 60,9% (FY2023: 60,7%), with the positive impact of the favourable sales mix more than offsetting the effects of regulated price cuts in Australia.
